英派药业-B今日盘中大涨15.59%，引起了市场的广泛关注。
消息面上，此次上涨可能受到多重因素驱动。首先，该股自上市以来经历获利回吐，股价从高点回落，今日迎来技术性反弹。其次，公司关联方在上市日进行了大额增持，释放了内部对公司前景的信心信号。更重要的是，公司的核心产品塞纳帕利已被纳入国家医保目录并从今年开始执行医保价格，这有望显著推动其营收放量。此外，公司在研管线中的IMP32作为全球首个靶向CEACAM5的双载荷ADC，具备First-in-Class（同类首创）地位，展现了强大的创新潜力，也增强了投资者的长期信心。
英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的生物技术公司，目前已进入商业化阶段。需要指出的是，公司目前仍处于亏损状态，营收尚无法完全覆盖高强度的研发投入，投资者在关注其增长潜力的同时，也需注意相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.